Skip to content

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00443872
Acronym
AtoZ
Enrollment
77
Registered
2007-03-06
Start date
2007-03-31
Completion date
2008-12-31
Last updated
2014-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's disease, Dopamine agonist adverse effects, MAO-B inhibitor, orally disintegrating selegiline, Zelapar

Brief summary

The purpose of the study is to determine if reducing or eliminating a dopamine agonist (DA) causing one of the side effects of daytime sleepiness, swelling of the lower legs or feet, hallucinations or impulsive behaviors while adding orally disintegrating selegiline can eliminate the adverse effect and maintain control of Parkinson's disease (PD) symptoms.

Detailed description

Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Levodopa is the most effective symptomatic treatment; however, long term use is associated with motor fluctuations (periods of return of PD symptoms when medication effect wears off) and dyskinesia (drug induced involuntary movements including chorea and dystonia). Once patients develop motor fluctuations treatment options include increasing the frequency of levodopa dosing, switching to sustained-release levodopa, adding other therapies including monoamine oxidase type B (MAO-B) inhibitors, dopamine agonists, catechol-o-methyltransferase (COMT) inhibitors and in patients with severe motor fluctuations deep brain stimulation surgery. There are no good evidence based studies indicating whether the use of one of these class of drugs is superior to the other nor are there treatment algorithms that recommend which class of drug should be initiated when the patients initially develop motor fluctuations. It is believed that the efficacy of the different drug classes is similar. However, the frequency of adverse effects may differ between drug classes, but such studies are lacking. In clinical practice when patients develop adverse effects to a drug from one class, a drug from another class is substituted in an attempt to maintain efficacy with reduced adverse effects. Dopamine agonists often have a higher risk of adverse effects compared to MAO B inhibitors. Therefore, the rationale for this study is that the addition of orally disintegrating selegiline after the reduction or discontinuation of the offending dopamine agonist will result in comparable efficacy with reduced adverse events. This study will assess the safety and efficacy of the addition of orally disintegrating selegiline in PD patients who are having adverse effects to dopamine agonists for which a dose reduction of the dopamine agonist is being considered. All patients in the study will receive orally disintegrating selegiline 1.25 mg once a day and the dose will be increased to 2.5 mg once a day if tolerated. Comparisons: The status of the adverse event at the end of the study while on orally disintegrating selegiline will be compared to the adverse event at the start of the study. In addition, efficacy will be compared at the start of the study while on the dopamine agonist to the end of the study with orally disintegrating selegiline.

Interventions

DRUGorally disintegrating selegiline (Zelapar)

1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated

Sponsors

Bausch Health Americas, Inc.
CollaboratorINDUSTRY
Parkinson's Disease and Movement Disorder Center of Boca Raton
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Idiopathic Parkinson's disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia,rigidity * Male or female outpatients * Age 30-90 years * Current use of levodopa (stable for at least 1 month) and a dopamine agonist (pramipexole or ropinirole) * Treatment response to current anti-parkinsonian medications in the opinion of the investigator * Dopamine agonist adverse effect that in the opinion of the investigator requires a reduction or discontinuation of the dopamine agonist. The adverse effects must be in one of the following four categories and should not be so severe as to require immediate discontinuation of the dopamine agonist (i.e., hallucinations without insight, serious impulsive behavior resulting in significant loss or danger to the patient). Daytime sleepiness - must score \>10 on Epworth Sleepiness Scale (ESS) at Baseline; Pedal edema - bothersome/concerning to patient; Hallucinations - insight should be maintained; Impulsive behavior - not including behaviors that are harmful to the patient requiring immediate discontinuation of the agonist. * Daily off time * Acceptable contraception for females of child bearing potential * Willing and able to comply with study procedures. * Willing and able to give written informed consent prior to beginning any study procedures.

Exclusion criteria

* Atypical parkinsonism due to drugs, metabolic disorders, encephalitis, trauma, or other neurodegenerative diseases. * Significant cognitive or psychiatric impairment which, in the opinion of the investigator, would interfere with the ability to complete all the tests required in the protocol. * Participation in another clinical drug trial within the previous four weeks. * Patients currently on monoamine oxidase type A or B (MAO-A or B) inhibitors, meperidine, tramadol, methadone, propoxyphene, dextromethorphan, and mirtazapine. * History of hypersensitivity or adverse reaction to selegiline or previous exposure to orally disintegrating selegiline * History of melanoma * Unstable/uncontrolled medical problems * History of drug/alcohol abuse

Design outcomes

Primary

MeasureTime frameDescription
Barratt Impulsiveness Scale Score for Those With Impulsive BehaviorBaseline and 3 monthsThis is a measure of impulsiveness. There are 30 questions regarding the presence of impulsive and non-impulsive behaviors each scored from 1 (rarely/never) to 4 (almost always/always). The total score reflects the sum of the 30 items. A higher score represents more impulsiveness.
Percentage of Participants With Reduction in Adverse Events3 MonthsThe primary outcome measure was the reduction of daytime sleepiness, hallucinations, pedal edema, and impulse control disorders after a reduction of dopamine agonist dose with the addition of an monoamine oxidase (MAO)-B inhibitor (orally disintegrating selegiline). Percentages of participants with reduction in individual adverse events as well as reduction in any adverse events are reported.
Epworth Sleepiness Scale Score for Those With Daytime SleepinessBaseline and 3 monthsThis is a measure of daytime sleepiness. The test is a list of eight situations in which one rates their tendency to become sleepy on a scale of 0, no change of dozing to 3, high chance of dozing. The total score ranges fro 0-24, with higher values representing excessive sleepiness. A score of greater than 10 represents clinically significant sleepiness.
Neuropsychiatric Inventory (NPI) Hallucinations Scale Score for Those With HallucinationsBaseline and 3 monthsReport of hallucinations with insight maintained based on the hallucinations questions of the Neuropsychiatric Inventory (NPI). The participant and their caregiver are asked a series of questions to determine if hallucinations are present. If present they rate the frequency of hallucinations on a scale of 1 (rarely, less than once a week) to 4, very often (once or more daily). They also rate the severity of the hallucinations, as mild (1 - present but harmless and cause little distress), moderate (2 - distressing and disruptive) or severe (3 - very disruptive, major source of behavioral disturbance, may need meds). The frequency and severity scores are multiplied (maximum score 12, with higher scores representing more distress/disability) for the total score.
Circumference of Lower Leg/Foot at Greatest Point of Swelling for Pedal EdemaBaseline and 3 monthsThe circumference of the lower leg/ankle with the greatest swelling was measured using a standard tape measure at baseline and 12 weeks for both the right and left ankles.

Secondary

MeasureTime frameDescription
Unified Parkinson's Disease Rating Scale (UPDRS) ScoresBaseline and 3 monthsThe UPDRS activities of daily living sub scale has 14 questions regarding the ability to perform daily activities like dressing, eating, etc. These questions are completed by the patient and each question has 5 responses ranging from 0 (no problems) to 4 (severe disability/cannot do). The total score for this sub scale is the sum of the scores for the 14 questions (higher scores represent greater disability), maximum score is 56. The motor assessment is completed by the investigator. There are 14 questions evaluating motor function in various body parts, representing 27 individual items (i.e., some questions, such as rigidity, are rated for 5 different body parts, other questions, such as finger tapping, are rated on both the right and left sides, and other questions are rated individually). Each item has 5 responses, 0 being none/no disability and 4 being the most severe disability. The 27 items are summed (higher scores represent greater disability); maximum score is 108.
PDQ-39 Quality of Life Assessment Total ScoresBaseline and 3 monthsThe PDQ-39 is a measure of quality of life, it has 8 sub scales and a total score. For this study only the total score was examined. There are a total of 39 questions related to the following 8 sub scales: ability/difficulty to perform motor activities, ability to perform daily activities, cognition, emotional well being, stigma, social support, communication, bodily discomfort; each question with 5 responses (0, no/never, 4 always). The total score is calculated by adding the scores for each of the 39 items, dividing by 39 x 4 (maximum score for all 39 items) and then multiplying by 100 to get a percentage score ranging from 0-100 with 100 representing the most disability and greatest impact on quality of life.
Beck Depression Inventory for All SubjectsBaseline and 3 monthsThe Beck Depression Inventory is a general measure of depression. There are 21 questions each with responses ranging from 0 (no issue or problem) to 3 (maximum issue/distress), all questions are related to emotions, mood, feelings, etc. The total possible score is 63 (higher scores represent more depression). The total score is calculated by adding the scores of the 21 items.
Beck Anxiety Inventory Scores for All SubjectsBaseline and 3 monthsThe Beck Anxiety Inventory is a general measure of anxiety. There are 21 questions each with responses ranging from 0 (no issue or problem) to 3 (severe - I could barely stand it), all questions are related to the presence of signs or symptoms of anxiety. The total possible score is 63 and a higher score represents greater anxiety. The total score is calculated by adding the responses for each of the 21 items.
Mini Mental State Examination (MMSE) Scores for All SubjectsBaseline and 3 monthsThe MMSE is a general measure of cognition (i.e., measures attention, memory, visuospatial construction, etc). It has 30 items, each item representing 1 point. The total score ranges from 0-30 with 30 being a perfect score (no cognitive impairment) and 0 being the lowest score (greatest possible level of impairment). The total score is calculated by adding the scores of each item.

Countries

United States

Participant flow

Recruitment details

Parkinson's disease (PD) patients with levodopa-induced motor fluctuations were enrolled at 12 sites in the United States. The first subject was enrolled in March 2007, and the last subject completed in September 2008.

Pre-assignment details

Excessive daytime sleepiness was defined by an Epworth Sleepiness Scale (ESS) score greater than 10; pedal edema was bothersome to the subject; hallucinations were bothersome, but insight was maintained; and impulse control disorders (ICDs) included behaviors not requiring immediate medical attention and not harmful to the patient or to others.

Participants by arm

ArmCount
PD Patients With DA Related AE
This is a one arm open label study of PD patients with a DA related AE
77
Total77

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event8
Overall StudyLost to Follow-up2
Overall StudyProtocol Violation7

Baseline characteristics

CharacteristicPD Patients With DA Related AE
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
46 Participants
Age, Categorical
Between 18 and 65 years
31 Participants
Age, Continuous66.9 years
STANDARD_DEVIATION 8.6
Region of Enrollment
United States
77 participants
Sex: Female, Male
Female
38 Participants
Sex: Female, Male
Male
39 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
57 / 77
serious
Total, serious adverse events
0 / 77

Outcome results

Primary

Barratt Impulsiveness Scale Score for Those With Impulsive Behavior

This is a measure of impulsiveness. There are 30 questions regarding the presence of impulsive and non-impulsive behaviors each scored from 1 (rarely/never) to 4 (almost always/always). The total score reflects the sum of the 30 items. A higher score represents more impulsiveness.

Time frame: Baseline and 3 months

Population: The number with ICDs at baseline

ArmMeasureGroupValue (MEAN)Dispersion
PD Patients With DA Related AEBarratt Impulsiveness Scale Score for Those With Impulsive BehaviorBaseline64.1 units on a scaleStandard Deviation 11.4
PD Patients With DA Related AEBarratt Impulsiveness Scale Score for Those With Impulsive Behavior3 months (12 weeks)61.3 units on a scaleStandard Deviation 12.4
p-value: <0.05Wilcoxon (Mann-Whitney)
Primary

Circumference of Lower Leg/Foot at Greatest Point of Swelling for Pedal Edema

The circumference of the lower leg/ankle with the greatest swelling was measured using a standard tape measure at baseline and 12 weeks for both the right and left ankles.

Time frame: Baseline and 3 months

Population: Presence of pedal edema at baseline

ArmMeasureGroupValue (MEAN)Dispersion
PD Patients With DA Related AECircumference of Lower Leg/Foot at Greatest Point of Swelling for Pedal EdemaLeft foot baseline25.8 centimetersStandard Deviation 3.4
PD Patients With DA Related AECircumference of Lower Leg/Foot at Greatest Point of Swelling for Pedal EdemaLeft foot 3 months (12 weeks)24.6 centimetersStandard Deviation 3.1
PD Patients With DA Related AECircumference of Lower Leg/Foot at Greatest Point of Swelling for Pedal EdemaRight foot baseline26.4 centimetersStandard Deviation 4.2
PD Patients With DA Related AECircumference of Lower Leg/Foot at Greatest Point of Swelling for Pedal EdemaRight Foot 3 months (12 weeks)25.2 centimetersStandard Deviation 4
Comparison: Change in pedal edema as measured by change in lower leg/ankle circumference in the left and right legsp-value: <0.01t-test, 2 sided
Primary

Epworth Sleepiness Scale Score for Those With Daytime Sleepiness

This is a measure of daytime sleepiness. The test is a list of eight situations in which one rates their tendency to become sleepy on a scale of 0, no change of dozing to 3, high chance of dozing. The total score ranges fro 0-24, with higher values representing excessive sleepiness. A score of greater than 10 represents clinically significant sleepiness.

Time frame: Baseline and 3 months

Population: Based only on the number of patients with excessive daytime sleepiness at baseline

ArmMeasureGroupValue (MEAN)Dispersion
PD Patients With DA Related AEEpworth Sleepiness Scale Score for Those With Daytime SleepinessBaseline13.5 units on a scaleStandard Deviation 3
PD Patients With DA Related AEEpworth Sleepiness Scale Score for Those With Daytime Sleepiness3 months (12 weeks)9.0 units on a scaleStandard Deviation 3.7
Comparison: Comparison of mean group scores at baseline and 12 weeksp-value: <0.01Wilcoxon (Mann-Whitney)
Primary

Neuropsychiatric Inventory (NPI) Hallucinations Scale Score for Those With Hallucinations

Report of hallucinations with insight maintained based on the hallucinations questions of the Neuropsychiatric Inventory (NPI). The participant and their caregiver are asked a series of questions to determine if hallucinations are present. If present they rate the frequency of hallucinations on a scale of 1 (rarely, less than once a week) to 4, very often (once or more daily). They also rate the severity of the hallucinations, as mild (1 - present but harmless and cause little distress), moderate (2 - distressing and disruptive) or severe (3 - very disruptive, major source of behavioral disturbance, may need meds). The frequency and severity scores are multiplied (maximum score 12, with higher scores representing more distress/disability) for the total score.

Time frame: Baseline and 3 months

Population: Patients who reported hallucinations at baseline

ArmMeasureGroupValue (MEAN)Dispersion
PD Patients With DA Related AENeuropsychiatric Inventory (NPI) Hallucinations Scale Score for Those With HallucinationsBaseline3.3 units on a scaleStandard Deviation 2.7
PD Patients With DA Related AENeuropsychiatric Inventory (NPI) Hallucinations Scale Score for Those With Hallucinations3 months (12 weeks)1.3 units on a scaleStandard Deviation 1.8
p-value: <0.01Wilcoxon (Mann-Whitney)
Primary

Percentage of Participants With Reduction in Adverse Events

The primary outcome measure was the reduction of daytime sleepiness, hallucinations, pedal edema, and impulse control disorders after a reduction of dopamine agonist dose with the addition of an monoamine oxidase (MAO)-B inhibitor (orally disintegrating selegiline). Percentages of participants with reduction in individual adverse events as well as reduction in any adverse events are reported.

Time frame: 3 Months

Population: 77 patients enrolled in the study and 60 completed. Each patient had to have at least one of the following DA related AEs, excessive daytime sleepiness, hallucinations, pedal edema or impulse control disorder (they could have more than one AE). 60 subjects were selected based on results of previous studies (discontinued patients were replaced).

ArmMeasureGroupValue (NUMBER)
PD Patients With DA Related AEPercentage of Participants With Reduction in Adverse EventsExcessive Daytime Sleepiness (n=50)94 percentage of participants
PD Patients With DA Related AEPercentage of Participants With Reduction in Adverse EventsHallucinations (n=15)86 percentage of participants
PD Patients With DA Related AEPercentage of Participants With Reduction in Adverse EventsPedal Edema (n=26)73 percentage of participants
PD Patients With DA Related AEPercentage of Participants With Reduction in Adverse EventsImpulse Control Disorder (n=25)84 percentage of participants
PD Patients With DA Related AEPercentage of Participants With Reduction in Adverse EventsAny Adverse Event (n=60)100 percentage of participants
Secondary

Beck Anxiety Inventory Scores for All Subjects

The Beck Anxiety Inventory is a general measure of anxiety. There are 21 questions each with responses ranging from 0 (no issue or problem) to 3 (severe - I could barely stand it), all questions are related to the presence of signs or symptoms of anxiety. The total possible score is 63 and a higher score represents greater anxiety. The total score is calculated by adding the responses for each of the 21 items.

Time frame: Baseline and 3 months

Population: All

ArmMeasureGroupValue (MEAN)Dispersion
PD Patients With DA Related AEBeck Anxiety Inventory Scores for All SubjectsBaseline11.5 units on a scaleStandard Deviation 9.7
PD Patients With DA Related AEBeck Anxiety Inventory Scores for All Subjects3 months (12 weeks)10.9 units on a scaleStandard Deviation 10.2
p-value: >0.05Wilcoxon (Mann-Whitney)
Secondary

Beck Depression Inventory for All Subjects

The Beck Depression Inventory is a general measure of depression. There are 21 questions each with responses ranging from 0 (no issue or problem) to 3 (maximum issue/distress), all questions are related to emotions, mood, feelings, etc. The total possible score is 63 (higher scores represent more depression). The total score is calculated by adding the scores of the 21 items.

Time frame: Baseline and 3 months

Population: All

ArmMeasureGroupValue (MEAN)Dispersion
PD Patients With DA Related AEBeck Depression Inventory for All SubjectsBaseline10.2 units on a scaleStandard Deviation 6.4
PD Patients With DA Related AEBeck Depression Inventory for All Subjects3 months (12 weeks)9.4 units on a scaleStandard Deviation 7.4
p-value: >0.05Wilcoxon (Mann-Whitney)
Secondary

Mini Mental State Examination (MMSE) Scores for All Subjects

The MMSE is a general measure of cognition (i.e., measures attention, memory, visuospatial construction, etc). It has 30 items, each item representing 1 point. The total score ranges from 0-30 with 30 being a perfect score (no cognitive impairment) and 0 being the lowest score (greatest possible level of impairment). The total score is calculated by adding the scores of each item.

Time frame: Baseline and 3 months

Population: All

ArmMeasureGroupValue (MEAN)Dispersion
PD Patients With DA Related AEMini Mental State Examination (MMSE) Scores for All SubjectsBaseline28.8 units on a scaleStandard Deviation 1.6
PD Patients With DA Related AEMini Mental State Examination (MMSE) Scores for All Subjects3 months (12 weeks)29.2 units on a scaleStandard Deviation 1.2
p-value: <0.05t-test, 2 sided
Secondary

PDQ-39 Quality of Life Assessment Total Scores

The PDQ-39 is a measure of quality of life, it has 8 sub scales and a total score. For this study only the total score was examined. There are a total of 39 questions related to the following 8 sub scales: ability/difficulty to perform motor activities, ability to perform daily activities, cognition, emotional well being, stigma, social support, communication, bodily discomfort; each question with 5 responses (0, no/never, 4 always). The total score is calculated by adding the scores for each of the 39 items, dividing by 39 x 4 (maximum score for all 39 items) and then multiplying by 100 to get a percentage score ranging from 0-100 with 100 representing the most disability and greatest impact on quality of life.

Time frame: Baseline and 3 months

ArmMeasureGroupValue (MEAN)Dispersion
PD Patients With DA Related AEPDQ-39 Quality of Life Assessment Total ScoresBaseline28.6 units on a scaleStandard Deviation 15.3
PD Patients With DA Related AEPDQ-39 Quality of Life Assessment Total Scores3 months (12 weeks)24.4 units on a scaleStandard Deviation 15.1
p-value: <0.01t-test, 2 sided
Secondary

Unified Parkinson's Disease Rating Scale (UPDRS) Scores

The UPDRS activities of daily living sub scale has 14 questions regarding the ability to perform daily activities like dressing, eating, etc. These questions are completed by the patient and each question has 5 responses ranging from 0 (no problems) to 4 (severe disability/cannot do). The total score for this sub scale is the sum of the scores for the 14 questions (higher scores represent greater disability), maximum score is 56. The motor assessment is completed by the investigator. There are 14 questions evaluating motor function in various body parts, representing 27 individual items (i.e., some questions, such as rigidity, are rated for 5 different body parts, other questions, such as finger tapping, are rated on both the right and left sides, and other questions are rated individually). Each item has 5 responses, 0 being none/no disability and 4 being the most severe disability. The 27 items are summed (higher scores represent greater disability); maximum score is 108.

Time frame: Baseline and 3 months

Population: All subjects completing the study were included

ArmMeasureGroupValue (MEAN)Dispersion
PD Patients With DA Related AEUnified Parkinson's Disease Rating Scale (UPDRS) ScoresADLs baseline11.9 units on a scaleStandard Deviation 5.8
PD Patients With DA Related AEUnified Parkinson's Disease Rating Scale (UPDRS) ScoresMotor baseline23.6 units on a scaleStandard Deviation 10.9
PD Patients With DA Related AEUnified Parkinson's Disease Rating Scale (UPDRS) ScoresADLs 3 months (12 weeks)10.3 units on a scaleStandard Deviation 5.1
PD Patients With DA Related AEUnified Parkinson's Disease Rating Scale (UPDRS) ScoresMotor 3 months (12 weeks)21.4 units on a scaleStandard Deviation 10.4
Comparison: This analysis is for the Activities of Daily Living (ADL) section of the scalep-value: <0.01Wilcoxon (Mann-Whitney)
p-value: <0.05Wilcoxon (Mann-Whitney)

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026